Date updated:02-04-2010
News of clinical trial results can make or break a drug. Here are ten companies expected to announce important results in coming months. Read more here.

-
AFFY
Affymax - $20.75
- 0.00%
- $N/A

-
ALTH
Allos Therapeutic - $7.90
- -0.50%
- $8.01

-
AMGN
Amgen Inc. - $57.43
- -0.10%
- $57.69

-
DCTH
Delcath Systems - $5.85
- -3.31%
- $5.86

-
GNVC
Genvec - $2.85
- +3.26%
- $2.80

-
ISIS
Isis Pharmaceutic - $9.69
- -2.91%
- $10.03

-
MDVN
Medivation - $12.82
- 0.00%
- $N/A

-
NVLT.OB
Novelos Therapeut - $0.25
- 0.00%
- $N/A
- 10 Biotech Stocks on Clinical Trials Watch's Blog
- No Blogs Found
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Fidelity Select Pharma...
- 3. Calamos Advisors
- 4. ProFunds Pharmaceutica...
- 5. BlackRock Health Scien...
- show all
- Top Do-It-Yourself Portfolios
- » jgroov Portfolio 1
- » ben johnson
- » my holdings
- » SC TRADE OF THE DAY
- » kudos
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Jonas Elmerraji Posted on March 15, 2010, at 8 a.m. EDT Financial reform should be this week’s biggest buzzword as details of Capitol Hill’s latest plans start t...
By Jonas Elmerraji Posted on March 12, 2010 Dividend-paying companies took a mini-break from hiking their payouts to shareholders last week. Only 14 companies announced...
By Roberto Pedone Posted on March 12, 2010 According to Jim Cramer, the stock market is trading higher for some very good reasons! In a March 11 RealMoney.com blog pos...
By Jonas Elmerraji Posted on March 11, 2010 The S&P 500 refuses to back down from its rally after posting gains in eight of the last 10 trading days. That’s a colossa...
A. Hi Ellen, I have not heard of Ormal but
whenever you have reservations about a
company, don't get in. There are so
many good company to put your money to
work.
A. The only one I own : SLX,
too hard pick a winner out all of them
TheStreet Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its safety first approach to investing aim... more
Here are some stocks that moved up on unusual volume on Mar. 12, 2010. more
Below is the list of the top open-market insider buys filed at the SEC on Mar. 12, 2010. more













Comments not available